GenSight Biologics Announces Presentation of Bilateral Visual Recovery From GS010 (LUMEVOQ™) Phase III Trials at the 46th Annual Meeting of NANOS

Print Friendly, PDF & Email

LHON RELATED:  GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announced today that the bilateral visual recovery observed with GS010 (LUMEVOQ™) in the REVERSE and RESCUE Phase III trials will […]